Small Interfering RNA Antihypertensive Drug Zilebesiran
Hypertension is one of the important risk factors of cardiovascular and cerebrovascular diseases.At present,the incidence rate of hypertension in China is high,while the awareness rate,diagnosis rate and treatment rate are relatively low.The pathogenesis of hypertension is complex,not fully understood,and has significant individual differences.Oral antihypertensive drugs are the main treatment method in Western medicine,with short medication intervals and poor compliance.Blood pressure control is still not enough in some patients after combination therapy.Zilebesiran is a new type of small interfering RNA antihypertensive drug that is still in the clinical research stage.It is proposed to specifically prevent the gene expression of liver angiotensinogen messenger RNA,thereby reducing the synthesis of angiotensinogen and achieving antihypertensive goals.The drug acts at a upstream site of traditional antihypertensive drugs,with a more comprehensive and potent effect,long half-life,and significantly reduced frequency of dosing.Current research findings suggest that its short-term use has good tolerability and safety.The aim is to introduce the mechanism of action and the preliminary results of clinical trials of zilebesiran,including its efficacy and safety,in order to enhance the comprehensive understanding of this drug among researchers in relevant fields in China.
NETL
NSTL
万方数据
